Oncology Analytics uses an evidence-based, data-supported system in order to deliver treatment options that are specifically tailored to the patient. Optimal treatments such as these that are aimed at the patient’s specific genetic profile are the future of cancer treatment. This is why Oncology Analytics recently won $21 million in Series B, raising its total funding to $28.5 million. The round was led by Oak HC/FT with McKesson Ventures, Sandbox Advantage, and BlueCross Blue Shield Venture Partners participating.
Mary Ann Azevedo file this report in Crunchbase News:
The Oncology Analytics e-Prior Authorization platform is used by physicians to support over 3.5 million health plan members in the US and Puerto Rico, according to the company. Oncology Analytics says it updates its platform “daily” to reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care.
In a press release, Oncology Analytics said it planned to use the new capital toward expanding its oncology benefits management capabilities and accelerating strategic investments in data analytics, data science, and innovative digital health technologies.
“With no end in sight to the rising costs and complexity of cancer treatment options – the oncology benefits management industry is in desperate need of both innovation and disruption,” Annie Lamont, managing partner of Oak HC/FT said in a written statement.
